HCA Healthcare (HCA) Stock Analysis 2026: 9.97x EV/EBITDA and 27.5% Margin of Safety Before April 24 Earnings

Price: $488.00 | Market Cap: $109.1B | Earnings: April 24, 2026

HCA Healthcare is the largest for-profit hospital operator in the United States — and one of the most frequently misread valuation stories in large-cap healthcare. When most screens surface HCA, two metrics immediately look alarming: a P/B ratio above 290x and an ROE above 136%. Both are artifacts of HCA's aggressive capital return strategy, not indicators of financial distress or bubble valuation. The company has returned so much capital through buybacks and dividends that book equity has been reduced to near zero — making P/B and ROE essentially meaningless as valuation inputs.

Once you look past the P/B distortion and focus on the metrics that actually matter for hospital operators — EV/EBITDA and forward PE — the picture is different: HCA trades at 9.97x EV/EBITDA and 15.82x forward earnings, with 6.7% revenue growth and a combined margin of safety of 27.5% on the Equity Rank model. For a company with 180+ hospitals, 2,300+ care sites, and structurally growing demand from an aging US population, that is not an expensive valuation.

Q1 2026 results arrive on April 24, five days away.

At a Glance

Understanding the P/B Distortion

The 291x P/B ratio that stops most retail screens in their tracks is not a sign that HCA is trading at an absurd premium to its assets. It is the mathematical consequence of a capital allocation strategy: HCA has returned so much cash to shareholders through buybacks and dividends over the past decade that the accounting book value of equity has been driven to near zero.

When a company repurchases its own shares, those buybacks reduce the equity line on the balance sheet — sometimes dramatically, to near-zero or even negative territory for highly capital-efficient, high-FCF businesses. HCA has bought back approximately $30+ billion in shares over the past decade. That capital returned to shareholders shows up as negative retained earnings on the balance sheet, mathematically compressing book equity and inflating the P/B ratio to seemingly impossible levels.

The same dynamic inflates ROE: with a very small equity denominator, even moderate net income produces an astronomical-looking return on equity.

The correct metrics for hospital operators: Enterprise Value to EBITDA and forward PE. These are the metrics hospital system buyers (private equity, other health systems) use in acquisitions, and they strip out the capital structure distortion.

At 9.97x EV/EBITDA, HCA sits within the normal range for large hospital operators — historically 8–12x depending on growth rate and macro environment. The 15.82x forward PE is reasonable for a healthcare services company growing revenue at 6.7% annually.

The Hospital Market: Structural Tailwinds

HCA's competitive position benefits from three structural dynamics that are difficult to replicate:

Scale in procurement and technology. With 180+ hospitals and 2,300+ care sites, HCA negotiates supply contracts, clinical technology, and staffing at a scale no regional competitor can match. The company's proprietary clinical data platform — the largest private clinical database in the country — enables quality measurement, staffing optimization, and care protocol standardization that smaller systems cannot afford to build.

Aging demographics. The 65+ population in the United States is the fastest-growing demographic segment and the highest consumer of hospital services. Procedures, admissions, and emergency volume all scale with age. This demographic tailwind runs for at least 15–20 years and is not cyclical.

Certificate of need and regulatory barriers. Many of HCA's core markets are in states that limit new hospital construction through Certificate of Need (CON) regulations. These regulations prevent competitors from building new facilities near existing hospitals, effectively maintaining local market structure. HCA's geographic concentration in the Sun Belt — Florida, Texas, and other high-growth states — positions it well for population growth migration.

Labor normalization. The single largest headwind to hospital margins in 2022–2023 was travel nursing costs. During the post-COVID surge period, hospitals competed for scarce travel nurses at premium rates, significantly compressing EBITDA margins. By 2025, travel nursing rates have normalized to pre-COVID levels and labor markets have stabilized. This normalization has been flowing through HCA's results as margin recovery, and any continuation of this trend in Q1 2026 will be a positive earnings signal.

Valuation: EV/EBITDA Is What Matters

Equity Rank's combined margin of safety of +27.5% reflects a weighted blend of methods calibrated for the healthcare sector. The 291x P/B is excluded from the consensus as a structural outlier; the model correctly identifies EV/EBITDA and PE as the primary applicable methods.

The forward PE comparison is particularly useful here: at 15.82x forward earnings, HCA is cheaper than the S&P 500 median (~20x) and slightly below the healthcare sector median (~18x), despite growing revenue at 6.7% — approximately two to three times the rate of most consumer staples, utilities, or financial companies that trade at similar multiples.

The hospital system peer comparison:

HCA trades at a modest premium to peers on EV/EBITDA, justified by its scale advantages, superior margins, and strong free cash flow conversion. Tenet and Community Health carry significantly more financial leverage, making their lower multiples appropriate risk adjustments rather than genuine discount opportunities.

Capital Allocation: The Buyback Engine

HCA's capital structure story is inseparable from its capital allocation philosophy. The company has historically generated substantial free cash flow — typically 15–20% of revenue — and has deployed that cash in three ways:

1. Acquisitions: Bolt-on hospital and surgery center acquisitions in existing markets to deepen local market density.
2. Capital expenditure: Hospital renovation, technology investment, and new facility construction in growth markets.
3. Shareholder returns: Buybacks and dividends, consuming the majority of remaining FCF.

The buyback program has been aggressive enough to reduce the float and drive book equity to near zero — which is why the P/B is 291x today. This capital return reduces the share count, boosts EPS over time, and concentrates ownership returns in the remaining shareholders.

The practical implication: HCA's earnings per share have grown faster than net income for years, because the denominator (share count) has been shrinking. This creates an EPS-growth tailwind that compounds the fundamental revenue growth.

Risk Factors

Regulatory and reimbursement risk. Hospital operators are deeply dependent on Medicare and Medicaid reimbursement rates. Any reduction in government healthcare reimbursement — through ACA changes, Medicaid expansion rollbacks, or CMS rate adjustments — would directly reduce HCA's revenue. This is the primary long-term regulatory risk for any for-profit hospital operator.

Macroeconomic sensitivity. HCA has a beta of 1.366 — meaningfully above 1.0 — reflecting that the stock is more volatile than the broad market. Hospital operators are somewhat cyclically sensitive: during recessions, elective procedures are deferred, uninsured patient volumes increase (reducing net revenue per admission), and Medicaid rolls expand (at lower reimbursement rates than commercial insurance).

Labor cost pressure. While travel nursing costs have normalized, the underlying healthcare labor market remains tight. Any resurgence in nursing or physician shortages could re-inflate operating costs.

Financial leverage. HCA carries substantial debt — the result of its acquisition strategy and buyback program. Higher interest rates increase debt service costs and reduce FCF available for returns. Net debt/EBITDA is approximately 3.5x, which is manageable but elevated relative to defensive healthcare companies.

Single-country concentration. Unlike global pharmaceutical companies, HCA generates nearly all revenue in the US. Any US-specific healthcare policy change has full impact on the company.

April 24 Earnings Preview

The Q1 2026 report on April 24 will be evaluated on four metrics:

1. Same-facility revenue growth. This is the organic growth rate stripping out acquisition contributions. Street consensus expects approximately 5–7% same-facility revenue growth. Any reading above 7% would indicate pricing power or volume strength beyond consensus.

2. Adjusted EBITDA margin. Q1 margin performance will signal whether labor cost normalization is holding. Management's prior guidance targeted continued margin expansion in 2026; Q1 is the first data point on whether that trajectory is on track.

3. Admissions and surgery volume. Volume is the key operating lever. Admissions growth above the prior year indicates either demographic-driven demand increase or market share gains. Any volume weakness would be concerning.

4. EPS vs. consensus. The current consensus Q1 EPS estimate is approximately $5.80–$6.10. A beat here combined with full-year guidance reiteration would likely drive the stock higher; a miss would pressure it materially given the beta of 1.366.

Equity Rank's Take

HCA Healthcare at $488 is one of the more straightforward large-cap healthcare opportunities on the Equity Rank screener. Once the P/B distortion is set aside and the analysis focuses on EV/EBITDA and forward PE, the stock looks modestly undervalued: 9.97x EV/EBITDA and 15.82x forward earnings for a company with structural demographic tailwinds, pricing power, and a track record of aggressive shareholder returns.

The 27.5% combined margin of safety reflects the model's view that HCA's earnings power is underpriced relative to peers. The primary risk is not the valuation — it is the macro and regulatory sensitivity captured in the 56.6 risk score and 1.366 beta. For investors comfortable with cyclical healthcare exposure, HCA is worth evaluating before April 24.

The EV/EBITDA Calculator lets you run HCA's 9.97x against peer hospital multiples directly. The DCF Calculator stress-tests the 6.7% growth assumption: at 5% long-term growth with 15% EBITDA margins, the implied enterprise value supports a per-share value above $550; at 3% growth, the implied value is approximately $480 — near current prices. The narrow downside at conservative assumptions is part of the bull case.

This article is for informational and educational purposes only. It does not constitute financial advice or a recommendation to purchase or sell HCA Healthcare, Inc. (HCA) shares or any other security. All scores, margin of safety estimates, and valuation outputs are model-based and subject to significant estimation uncertainty. The combined margin of safety of +27.5% reflects the blended average of multiple valuation methodologies; the P/B method is excluded from the consensus due to the capital structure distortion created by HCA's buyback program. The P/B ratio of 291x and ROE of 136% are mathematical artifacts of near-zero book equity, not indicators of overvaluation or financial strength — investors should not interpret these figures at face value. EV/EBITDA of 9.97x and forward PE of 15.82x are the methodologically appropriate primary metrics for hospital operator valuation. Revenue growth of 6.7% TTM reflects trailing performance; forward growth rates may differ. HCA carries approximately 3.5x net debt/EBITDA; leverage increases sensitivity to interest rate changes and reduces financial flexibility. Regulatory risk is material: Medicare and Medicaid reimbursement rate changes are the primary long-term revenue risk and are difficult to predict. Labor cost normalization may not persist; any resurgence in travel nursing demand or healthcare labor shortages would compress margins. The beta of 1.366 implies meaningfully above-average market volatility; the risk score of 56.6 reflects moderate-to-high risk relative to the screener universe. The April 24, 2026 earnings report may move the stock materially in either direction. Past financial performance does not guarantee future results. All investments involve risk, including potential loss of principal. Equity Rank is not a registered investment adviser. Always conduct your own due diligence and consult a qualified financial adviser before making investment decisions.